Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WA | N.MMED.WR | N.MMED.WS | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > MindMed Adds MDMA To R&D Pipeline

<< Previous

Bullboard Posts

Next >>

Comment by R013013Con Jun 08, 2020 10:23pm

413 Views

Post# 31127116

RE:MindMed Adds MDMA To R&D Pipeline

MDMA, phase 3 clinical trial has an estimated study completion date of June 18, 2020.

If it gets FDA approved and moved on to phase 4, this has potential to be big news.

JLUTZ1 wrote:

Mind Medicine, also known as MindMed this morning announced that it is branching out its research and development pipeline to include that of the psychedelic compound MDMA as it looks to further psychedelic research.

https://thedeepdive.ca/mindmed-adds-mdma-to-rd-pipeline/